HLB PEP, a leading peptide material company, announced on Thursday that it has entered into a contract with Reprocell, a Japanese cell therapy firm, to supply customized neo-antigen peptide raw materials tailored to individual patient characteristics.
This personalized treatment approach involves analyzing patients to identify cancer-specific neo-antigens, which are then manufactured into peptides.
Neo-antigens are novel proteins that emerge during the genetic mutation process of cancer cells.
These neo-antigens are uniquely expressed on cancer cell surfaces and absent in normal cells, allowing for targeted cancer treatment without harming healthy tissue.
Under this agreement, HLB PEP will produce neo-antigen-derived peptides at its state-of-the-art facility using a contract development and manufacturing organization (CDMO) model.
Both companies are committed to expanding their collaboration beyond Japan, eyeing global markets. In response to the growing demand for CDMO services, HLB PEP is proactively expanding its facilities.
Shim Kyung-jae, Chief Executive Officer (CEO) of HLB Peptide, stated that by consistently delivering neo-antigen peptides crucial for patient-specific treatments, it aim to play an increasingly significant role in advancing precision medicine.
He further added that this partnership with Reprocell serves as a springboard for the expansion into the global market, beyond Japan. They’re also committed to continuously enhancing the production capabilities to meet the rising demand for CDMO services.
